AIROMIR

This brand name is authorized in Australia, Canada, Finland, France, Hong Kong, Netherlands, United Kingdom, South Africa

Active ingredients

The drug AIROMIR contains one active pharmaceutical ingredient (API):

1 Salbutamol UNII 021SEF3731 - ALBUTEROL SULFATE

Salbutamol is a selective β2-agonist providing short-acting (4-6 hour) bronchodilation with a fast onset (within 5 minutes) in reversible airways obstruction. At therapeutic doses it acts on the β2-adrenoceptors of bronchial muscle. Salbutamol is administered for the symptomatic relief of bronchospasm associated with chronic or acute asthma, bronchitis or other obstructive pulmonary diseases. Read about Salbutamol

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
R03AC02	Salbutamol	R Respiratory system → R03 Drugs for obstructive airway diseases → R03A Adrenergics, inhalants → R03AC Selective beta-2-adrenoreceptor agonists
Discover more medicines within R03AC02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 8354Q
Country: CA	Health Products and Food Branch	Identifier(s): 02232570
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 125587, 393287
Country: FR	Base de données publique des médicaments	Identifier(s): 66086181
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 14785, 32145
Country: HK	Department of Health Drug Office	Identifier(s): 39786
Country: NL	Z-Index G-Standaard	Identifier(s): 14898543, 14898551
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 43281, 53007
Country: ZA	Health Products Regulatory Authority	Identifier(s): 30/10.2.1/0032